We previously developed a nanobody, NJB2, specific for a domain of fibronectin (FN-EIIIB), which is expressed selectively in many tumor types including triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC) and their metastases (1). Here, FN1 is linked to triple-negative breast carcinoma.